EA202190736A1 - Способы и композиции для увеличения экспрессии белка и/или лечения расстройства, связанного с гаплонедостаточностью - Google Patents

Способы и композиции для увеличения экспрессии белка и/или лечения расстройства, связанного с гаплонедостаточностью

Info

Publication number
EA202190736A1
EA202190736A1 EA202190736A EA202190736A EA202190736A1 EA 202190736 A1 EA202190736 A1 EA 202190736A1 EA 202190736 A EA202190736 A EA 202190736A EA 202190736 A EA202190736 A EA 202190736A EA 202190736 A1 EA202190736 A1 EA 202190736A1
Authority
EA
Eurasian Patent Office
Prior art keywords
haplon
insufficiency
compositions
treatment
methods
Prior art date
Application number
EA202190736A
Other languages
English (en)
Russian (ru)
Inventor
Джеффри М Коллер
Томас Свит
Харви Лодиш
Original Assignee
Кейс Вестерн Ризерв Юниверсити
Уайтхед Инститьют Фо Байомедикал Рисёрч
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кейс Вестерн Ризерв Юниверсити, Уайтхед Инститьют Фо Байомедикал Рисёрч filed Critical Кейс Вестерн Ризерв Юниверсити
Publication of EA202190736A1 publication Critical patent/EA202190736A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/34—Allele or polymorphism specific uses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C12N2330/51—Specially adapted vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
EA202190736A 2018-09-26 2019-09-26 Способы и композиции для увеличения экспрессии белка и/или лечения расстройства, связанного с гаплонедостаточностью EA202190736A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862736847P 2018-09-26 2018-09-26
PCT/US2019/053268 WO2020069199A1 (en) 2018-09-26 2019-09-26 Methods and compositions for increasing protein expression and/or treating a haploinsufficiency disorder

Publications (1)

Publication Number Publication Date
EA202190736A1 true EA202190736A1 (ru) 2021-09-16

Family

ID=69949913

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190736A EA202190736A1 (ru) 2018-09-26 2019-09-26 Способы и композиции для увеличения экспрессии белка и/или лечения расстройства, связанного с гаплонедостаточностью

Country Status (15)

Country Link
US (2) US12281314B2 (cg-RX-API-DMAC7.html)
EP (1) EP3856905A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022502044A (cg-RX-API-DMAC7.html)
KR (1) KR102814622B1 (cg-RX-API-DMAC7.html)
CN (1) CN113195719A (cg-RX-API-DMAC7.html)
AU (1) AU2019350871B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021005788A2 (cg-RX-API-DMAC7.html)
CA (1) CA3114109A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021000747A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021005040A2 (cg-RX-API-DMAC7.html)
EA (1) EA202190736A1 (cg-RX-API-DMAC7.html)
IL (1) IL281848A (cg-RX-API-DMAC7.html)
MX (1) MX2021003567A (cg-RX-API-DMAC7.html)
WO (1) WO2020069199A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202102302B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7712270B2 (ja) 2019-11-01 2025-07-23 テバード バイオサイエンシズ インコーポレイテッド 未成熟終止コドン媒介障害を処置するための方法および組成物
CA3160097A1 (en) * 2019-11-04 2021-05-14 Flagship Pioneering, Inc. Trem compositions for con-rare codons and related uses
US20230203510A1 (en) * 2020-05-29 2023-06-29 Flagship Pioneering Innovations Vi, Llc Trem compositions and methods relating thereto
EP4158032A2 (en) * 2020-05-29 2023-04-05 Flagship Pioneering Innovations VI, LLC Trem compositions and methods relating thereto
EP4334450A4 (en) * 2021-05-05 2025-06-18 Tevard Biosciences, Inc. Methods and compositions for treating a premature termination codon-mediated disorder
CA3249261A1 (en) 2022-04-18 2023-10-26 Vertex Pharmaceuticals Incorporated COMPOSITIONS AND PROCESSES TO IMPROVE ADENE-ASSOCIATED VIRUS (AAV) THERAPY AND REDUCE AAV TROPISM TO THE LIVER
CN117257958B (zh) * 2023-11-21 2024-02-09 四川大学华西医院 Trps1抑制剂的新用途及用于治疗和/或预防雄激素性秃发的药物
WO2025176166A1 (en) * 2024-02-21 2025-08-28 Zhuhai Codone Biotechnology Co., Ltd. Engineered trna expression cassette
WO2026001270A1 (en) * 2024-06-24 2026-01-02 Zhuhai Codone Biotechnology Co., Ltd. Engineered trna molecules and methods

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1114149A1 (en) 1998-09-17 2001-07-11 SmithKline Beecham Corporation Rnase p polypeptides
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
JP4406731B2 (ja) * 2005-03-31 2010-02-03 国立大学法人 岡山大学 部位特異的アミノ酸導入法のための新規な直交化tRNA
WO2008127900A1 (en) * 2007-04-13 2008-10-23 The Salk Institute For Biological Studies Methods of genetically encoding unnatural amino acids in eukaryotic cells using orthogonal trna/synthetase pairs
US20120283116A1 (en) * 2009-09-11 2012-11-08 Leppert Mark F Mutant Sodium Channel Nav1.7 and Methods Related Thereto
US9676810B2 (en) * 2010-07-08 2017-06-13 The Brigham And Women's Hospital, Inc. Neuroprotective molecules and methods of treating neurological disorders and inducing stress granules
US20130129668A1 (en) * 2011-09-01 2013-05-23 The Regents Of The University Of California Diagnosis and treatment of arthritis using epigenetics
WO2014052855A1 (en) 2012-09-27 2014-04-03 Population Diagnostics, Inc. Methods and compositions for screening and treating developmental disorders
EP3052624A1 (en) 2013-10-02 2016-08-10 Wageningen Universiteit Systematic optimization of coding sequence for functional protein expression
EP3362087A1 (en) 2015-10-15 2018-08-22 The Scripps Research Institute BINDING ACTIVITY OF AMINOACYL-tRNA SYNTHETASE IN CHARCOT-MARIE-TOOTH (CMT) NEUROPATHY AND CMT-RELATED NEUROLOGICAL DISEASES
CN116059236A (zh) * 2015-12-14 2023-05-05 冷泉港实验室 用于治疗常染色体显性精神发育迟滞5型和Dravet综合征的反义寡聚体
WO2017193051A1 (en) 2016-05-06 2017-11-09 The Trustees Of Princeton University Methods of monitoring rnase l activity
PL3458074T3 (pl) * 2016-05-16 2024-11-12 Board Of Regents Of The University Of Texas System KOMPOZYCJA DO DOSTARCZANIA tRNA W POSTACI NANOCZĄSTEK I SPOSOBY ICH STOSOWANIA
WO2018104385A1 (en) 2016-12-07 2018-06-14 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Codon optimization
JP2022534988A (ja) 2019-05-31 2022-08-04 フラッグシップ パイオニアリング, インコーポレイテッド tRNAプールを調節するためのTREMの使用

Also Published As

Publication number Publication date
US20220073933A1 (en) 2022-03-10
KR20210091699A (ko) 2021-07-22
JP2022502044A (ja) 2022-01-11
ZA202102302B (en) 2022-04-28
KR102814622B1 (ko) 2025-05-29
IL281848A (en) 2021-05-31
AU2019350871A1 (en) 2021-05-20
EP3856905A4 (en) 2023-06-21
CO2021005040A2 (es) 2021-09-20
CA3114109A1 (en) 2020-04-02
AU2019350871B2 (en) 2026-02-26
BR112021005788A2 (pt) 2021-10-26
JP2025010148A (ja) 2025-01-20
US12281314B2 (en) 2025-04-22
CN113195719A (zh) 2021-07-30
WO2020069199A1 (en) 2020-04-02
US20260009041A1 (en) 2026-01-08
EP3856905A1 (en) 2021-08-04
CL2021000747A1 (es) 2021-10-22
MX2021003567A (es) 2021-08-24

Similar Documents

Publication Publication Date Title
MX2021003567A (es) Métodos y composiciones para aumentar la expresión de proteínas y/o tratar un trastorno por haploinsuficiencia.
AR124871A2 (es) Métodos de fabricación para el control del contenido de lisina c-terminal, galactosa y ácido siálico en proteínas recombinantes
ZA202213661B (en) Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
MY189819A (en) Genetically modified cells and uses thereof
EA201992001A1 (ru) Композиции и способы повышения экспрессии генов
CY1121217T1 (el) Μεθοδοι για συγκομιδη καλλιεργειων κυτταρου θηλαστικων
NZ759034A (en) Viral vectors encoding recombinant fix with increased expression for gene therapy of hemophilia b
MX2021005715A (es) Derivacion sin alimentadores de celulas madre pluripotentes inducidas humanas con arn mensajero sintetico.
EA201790405A1 (ru) Композиции и способы лечения метаболических расстройств
EA201890137A1 (ru) Среда для культивирования клеток с добавлением таурина и способы применения
MY195318A (en) Multispecific Antibody Constructs
AR100606A1 (es) Variantes de lipasas y polinucleótidos que las codifican
SG10201806217UA (en) Culture medium composition
EP3666755A4 (en) COMPLETE CONTINUOUS FLOW ONLINE PRODUCTION PROCESS FOR THE DIRECT PREPARATION OF ORGANIC PEROXIDE USING HYDROGEN PEROXIDE AS THE RAW MATERIAL
MX2018004121A (es) Receptores de antigeno y usos de los mismos.
EA202092049A1 (ru) Вирусные векторы, кодирующие рекомбинантные варианты fviii с повышенной экспрессией для генной терапии гемофилии a
PH12020550023A1 (en) Compositions for treating stress-related disorders
EA201791318A1 (ru) Дрожжи для приготовления алкогольных напитков
MX2018012872A (es) Composiciones y metodos para mejorar la expresion genetica de pklr.
MX388883B (es) Mutaciones en proteinas del grupo hierro-azufre que mejoran la utilizacion de xilosa.
MY193535A (en) Cell culture methods
MX2017012223A (es) Metodo de produccion con iones de cobre controlados.
MX2015010887A (es) Formulaciones y metodos para aumentar la produccion de proteinas recombinantes.
PH12016502343A1 (en) Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger rna
EA201890720A1 (ru) Лечение диабетической периферической нейропатии с применением плацентарных клеток